Clinical Trial Update: Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase II open-label multicenter study to evaluate HLX43, an anti-PD-L1 antibody-drug conjugate, in subjects with advanced colorectal cancer; the trial is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• HLX43

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Colorectal Cancer (CRC) | Phase 2 | Status: RECRUITING